Close Menu

NEW YORK – Infectious disease diagnostics company MeMed said on Tuesday that it has received the CE-IVD mark for its MeMed BV diagnostic test and its point-of-care MeMed Key platform.

With the clearance MeMed can begin offering the BV test at the point of care. The test measures a set of three host-response proteins to help distinguish between bacterial and viral infections and guide antibiotic use.

The company already offered a CE-IVD-marked ELISA version of the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 


As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.